三阴性乳腺癌免疫治疗的进展与展望
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
TNBC仅占新发乳腺癌诊断的约15%-20%;
31.3分
★☆☆☆☆
FRONTIER PAPERS
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
TNBC仅占新发乳腺癌诊断的约15%-20%;
Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs.
肿瘤免疫治疗对改善肿瘤患者的预后有显著贡献。
共 2 条
MEMBER ACCOUNT
登录成功会直接打开下一页。